SG11201408095XA - Fibroblast growth factor 21 proteins - Google Patents
Fibroblast growth factor 21 proteinsInfo
- Publication number
- SG11201408095XA SG11201408095XA SG11201408095XA SG11201408095XA SG11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA
- Authority
- SG
- Singapore
- Prior art keywords
- indiana
- indianapolis
- company
- international
- eli lilly
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 102000056713 human FGF21 Human genes 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
- Y10S530/814—Cellulose or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658104P | 2012-06-11 | 2012-06-11 | |
| US201361777386P | 2013-03-12 | 2013-03-12 | |
| PCT/US2013/044190 WO2013188181A1 (fr) | 2012-06-11 | 2013-06-05 | Protéines du facteur de croissance des fibroblastes 21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408095XA true SG11201408095XA (en) | 2015-01-29 |
Family
ID=48670814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408095XA SG11201408095XA (en) | 2012-06-11 | 2013-06-05 | Fibroblast growth factor 21 proteins |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8741841B2 (fr) |
| EP (1) | EP2858662B1 (fr) |
| JP (1) | JP6182600B2 (fr) |
| KR (1) | KR20150006060A (fr) |
| CN (1) | CN104394882B (fr) |
| AR (1) | AR091216A1 (fr) |
| AU (1) | AU2013274638A1 (fr) |
| BR (1) | BR112014029966A2 (fr) |
| CA (1) | CA2871145A1 (fr) |
| CL (1) | CL2014003078A1 (fr) |
| CO (1) | CO7151525A2 (fr) |
| EA (1) | EA201492053A1 (fr) |
| EC (1) | ECSP14030742A (fr) |
| ES (1) | ES2644787T3 (fr) |
| HK (1) | HK1203357A1 (fr) |
| IL (1) | IL235832A0 (fr) |
| IN (1) | IN2014MN02132A (fr) |
| MX (1) | MX2014015257A (fr) |
| PE (1) | PE20150201A1 (fr) |
| PH (1) | PH12014502766A1 (fr) |
| SG (1) | SG11201408095XA (fr) |
| TN (1) | TN2014000439A1 (fr) |
| TW (1) | TWI513705B (fr) |
| WO (1) | WO2013188181A1 (fr) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523084A (ja) | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| PL2726511T3 (pl) | 2011-07-01 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| KR20150006059A (ko) * | 2012-06-11 | 2015-01-15 | 일라이 릴리 앤드 캄파니 | 섬유모세포 성장 인자 21 변이체 |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| NZ630484A (en) | 2012-11-28 | 2017-04-28 | Ngm Biopharmaceuticals Inc | Compositions and methods for treatment of metabolic disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| EP2938740B1 (fr) | 2012-12-27 | 2022-04-20 | NGM Biopharmaceuticals, Inc. | Peptides chimériques fgf19 pour l'utilisation dans le traitement de maladies de l'acide biliaire |
| MX2016004822A (es) | 2013-10-28 | 2016-08-17 | Ngm Biopharmaceuticals Inc | Modelos de cancer y metodos asociados. |
| HUE050279T2 (hu) | 2014-01-24 | 2020-11-30 | Ngm Biopharmaceuticals Inc | Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei |
| US10077319B2 (en) | 2014-02-21 | 2018-09-18 | Medimmune, Llc | Anti-PCSK9-GLP-1 fusions and methods for use |
| WO2015138278A1 (fr) | 2014-03-11 | 2015-09-17 | Novartis Ag | Méthodes de traitement de troubles métaboliques associés à des lipodystrophies et à des défauts dans la production ou la signalisation de l'insuline |
| WO2015148708A1 (fr) | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Agonistes du récepteur fgf21 et leurs utilisations |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| EP3155005A4 (fr) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire |
| US10293026B2 (en) | 2014-09-08 | 2019-05-21 | Osaka University | Agent for preventing or treating demyelinating disease |
| IL251834B2 (en) | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions containing peptide variants and methods of using them |
| TWI705071B (zh) | 2014-10-24 | 2020-09-21 | 美商必治妥美雅史谷比公司 | 經修飾之fgf-21多肽及其用途 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| KR20160088656A (ko) | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| WO2016187558A2 (fr) | 2015-05-20 | 2016-11-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Procédé visant à améliorer l'issue neurologique chez des patients dont la température est modifiée à des fins thérapeutiques |
| WO2017019957A2 (fr) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Protéines de liaison et leurs procédés d'utilisation |
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| ES2871036T3 (es) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Método para el tratamiento de trastornos relacionados con ácidos biliares |
| CN105348380B (zh) * | 2015-12-28 | 2019-03-01 | 江苏康缘瑞翱生物医药科技有限公司 | 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759696A (zh) | 2016-08-19 | 2018-03-06 | 安源医药科技（上海）有限公司 | 人白介素7融合蛋白及其制备方法 |
| WO2018032638A1 (fr) | 2016-08-19 | 2018-02-22 | 安源医药科技（上海）有限公司 | Peptide de liaison pour la construction d'une protéine de fusion |
| WO2018039557A1 (fr) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19 |
| JP7328891B2 (ja) | 2016-11-10 | 2023-08-17 | ユーハン・コーポレイション | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
| JP7181886B2 (ja) | 2017-03-14 | 2022-12-01 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質 |
| EP3612637A4 (fr) | 2017-04-21 | 2021-01-27 | Yuhan Corporation | Procédé de production de protéines à double fonction et ses dérivés |
| CN107385020A (zh) * | 2017-06-23 | 2017-11-24 | 西安医学院 | 瘦素在人重组fgf21蛋白活性检测中的应用 |
| SG11202001379WA (en) | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| EP3749683A4 (fr) | 2018-02-08 | 2022-03-16 | Sunshine Lake Pharma Co., Ltd. | Variant de fgf21, protéine de fusion et son application |
| BR112020026512A2 (pt) | 2018-07-03 | 2021-04-06 | Bristol-Myers Squibb Company | Formulações de fgf-21 |
| CN111195234B (zh) * | 2018-11-16 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组FGF21-Fc融合蛋白冻干粉制剂 |
| WO2020177712A1 (fr) * | 2019-03-05 | 2020-09-10 | Dongguan Hec Biopharmaceutical R&D Co., Ltd. | Molécule polypeptidique et son application |
| MX2022008336A (es) | 2020-01-08 | 2022-08-08 | Bristol Myers Squibb Co | Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21). |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| JP2023538533A (ja) | 2020-08-07 | 2023-09-08 | ブリストル－マイヤーズ スクイブ カンパニー | 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１ |
| KR20220021207A (ko) | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
| KR102495299B1 (ko) * | 2020-11-03 | 2023-02-06 | 토드제약 주식회사 | Fgf21의 열탄력성을 이용한 fgf21 생산 방법 |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| AU2002322394A1 (en) | 2001-07-30 | 2003-02-17 | Eli Lilly And Company | Method for treating diabetes and obesity |
| BRPI0416683A (pt) * | 2003-12-10 | 2007-01-30 | Lilly Co Eli | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 |
| ATE444306T1 (de) * | 2004-05-13 | 2009-10-15 | Lilly Co Eli | Fgf-21-fusionsproteine |
| JP2010523084A (ja) * | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| CH699521A2 (de) | 2008-09-09 | 2010-03-15 | Rotorcraft Ag | Streckwerk für eine Strickmaschine. |
| CN102625811B (zh) | 2008-10-10 | 2016-09-21 | 安姆根有限公司 | Fgf21突变体及其用途 |
| WO2010065439A1 (fr) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants de facteurde croissance 21 du fibroblaste |
| MX2011007544A (es) | 2009-01-23 | 2011-08-12 | Novo Nordisk As | Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso. |
| UY32607A (es) | 2009-05-05 | 2010-12-31 | Amgen Inc | Mutantes de fgf21 y usos del mismo |
| US20120052069A1 (en) * | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| JP2013533227A (ja) * | 2010-06-08 | 2013-08-22 | ノヴォ ノルディスク アー／エス | Ｆｇｆ２１類似体および誘導体 |
| AR087973A1 (es) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
-
2013
- 2013-05-27 TW TW102118698A patent/TWI513705B/zh not_active IP Right Cessation
- 2013-05-30 AR ARP130101904 patent/AR091216A1/es unknown
- 2013-06-05 PE PE2014002236A patent/PE20150201A1/es not_active Application Discontinuation
- 2013-06-05 JP JP2015517297A patent/JP6182600B2/ja active Active
- 2013-06-05 CA CA2871145A patent/CA2871145A1/fr not_active Abandoned
- 2013-06-05 CN CN201380030788.4A patent/CN104394882B/zh not_active Expired - Fee Related
- 2013-06-05 US US13/910,149 patent/US8741841B2/en active Active
- 2013-06-05 EA EA201492053A patent/EA201492053A1/ru unknown
- 2013-06-05 IN IN2132MUN2014 patent/IN2014MN02132A/en unknown
- 2013-06-05 ES ES13730733.6T patent/ES2644787T3/es active Active
- 2013-06-05 EP EP13730733.6A patent/EP2858662B1/fr active Active
- 2013-06-05 KR KR20147034366A patent/KR20150006060A/ko active IP Right Grant
- 2013-06-05 SG SG11201408095XA patent/SG11201408095XA/en unknown
- 2013-06-05 WO PCT/US2013/044190 patent/WO2013188181A1/fr active Application Filing
- 2013-06-05 BR BR112014029966A patent/BR112014029966A2/pt not_active IP Right Cessation
- 2013-06-05 MX MX2014015257A patent/MX2014015257A/es unknown
- 2013-06-05 AU AU2013274638A patent/AU2013274638A1/en not_active Abandoned
-
2014
- 2014-04-23 US US14/259,210 patent/US8927492B2/en active Active
- 2014-10-20 TN TN2014000439A patent/TN2014000439A1/fr unknown
- 2014-11-13 CL CL2014003078A patent/CL2014003078A1/es unknown
- 2014-11-20 IL IL235832A patent/IL235832A0/en unknown
- 2014-11-27 CO CO14261559A patent/CO7151525A2/es unknown
- 2014-12-10 PH PH12014502766A patent/PH12014502766A1/en unknown
- 2014-12-11 EC ECIEPI201430742A patent/ECSP14030742A/es unknown
-
2015
- 2015-04-20 HK HK15103818.7A patent/HK1203357A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2858662A1 (fr) | 2015-04-15 |
| JP2015527974A (ja) | 2015-09-24 |
| MX2014015257A (es) | 2015-03-05 |
| PH12014502766A1 (en) | 2015-02-09 |
| US8741841B2 (en) | 2014-06-03 |
| EP2858662B1 (fr) | 2017-08-09 |
| HK1203357A1 (en) | 2015-10-30 |
| BR112014029966A2 (pt) | 2017-09-12 |
| US20140228282A1 (en) | 2014-08-14 |
| IL235832A0 (en) | 2015-01-29 |
| JP6182600B2 (ja) | 2017-08-16 |
| CN104394882A (zh) | 2015-03-04 |
| EA201492053A1 (ru) | 2015-02-27 |
| KR20150006060A (ko) | 2015-01-15 |
| CO7151525A2 (es) | 2014-12-29 |
| TW201408693A (zh) | 2014-03-01 |
| AU2013274638A1 (en) | 2014-11-06 |
| CN104394882B (zh) | 2016-06-22 |
| ES2644787T3 (es) | 2017-11-30 |
| IN2014MN02132A (fr) | 2015-09-11 |
| PE20150201A1 (es) | 2015-02-19 |
| WO2013188181A1 (fr) | 2013-12-19 |
| TN2014000439A1 (en) | 2016-03-30 |
| AR091216A1 (es) | 2015-01-21 |
| CA2871145A1 (fr) | 2013-12-19 |
| ECSP14030742A (es) | 2015-09-30 |
| US8927492B2 (en) | 2015-01-06 |
| US20130330336A1 (en) | 2013-12-12 |
| TWI513705B (zh) | 2015-12-21 |
| CL2014003078A1 (es) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201408261UA (en) | Syringe | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same |